Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

(2017) C. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target

(2012) L. Gandhi et al.   CLINICAL CANCER RESEARCH

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

Gender Specific Drug Metabolism of PF-02341066 in Rats — Role of Sulfoconjugation

(2010) Wei-Zhu Zhong et al.   CURRENT DRUG METABOLISM

Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

(2010) S. Yamazaki et al.   DRUG METABOLISM AND DISPOSITION

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

(2010) Filip Janku et al.   Nature Reviews Clinical Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human radiolabeled mass balance studies: objectives, utilities and limitations

(2009) Natalia Penner et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical Development

(2009) Laurent Leclercq et al.   CHEMICAL RESEARCH IN TOXICOLOGY

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction

(2008) M. Shou et al.   DRUG METABOLISM AND DISPOSITION

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA